Biomind Labs Inc.
Biomind Labs Inc.
Your view on BMNDF
Overview
What the company does, where it operates, and who runs it.
About Biomind Labs Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Alejandro Antalich
- Headquarters
- Building Ceibo Of. 002, Canelones, UY
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Alejandro Antalich
- Headquarters
- Building Ceibo Of. 002, Canelones, UY
Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions.
The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; and BMND08, a 5-Methoxy-N,N-dimethyltryptamine based candidate that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer's-type cognitive impairment.
It is also developing new and preclinical drug candidates, including BMND02 for treating fibromyalgia, BMND03 for treating addictive disorders, BMND05 for treating chronic pain, BMND06 for treating inflammation, and BMND07 for treating major depressive disorder. The company is headquartered in Canelones, Uruguay.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Biomind Labs Inc., and the rating behind it. BMNDF last traded at $0.11; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Biomind Labs Inc.. Starting points for Biomind Labs Inc.: EPS -$0.02, beta -0.75 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Biomind Labs Inc.. Biomind Labs Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Biomind Labs Inc.. Trailing twelve-month EPS for Biomind Labs Inc. stands at -$0.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Biomind Labs Inc.. Biomind Labs Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Biomind Labs Inc. valued side by side against its closest peers. Biomind Labs Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Biomind Labs Inc., and how their positions are changing. At a $8.8M market value, institutional positions materially move Biomind Labs Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Biomind Labs Inc. executives and directors. Shares of Biomind Labs Inc. have traded between $0.02 and $0.70 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Biomind Labs Inc.. Biomind Labs Inc. is a $8.8M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Biomind Labs Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Biomind Labs Inc.. Coverage tracks Biomind Labs Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.